Secondary Logo

Institutional members access full text with Ovid®

Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis

Plaçais, Léoa; Hau, Estellea; Delyon, Juliea; Azoulay, Elieb; Gautier, Jean-Francoisc; Lebbé, Célestea; Baroudjian, Barouyra the PATIO Group

doi: 10.1097/CMR.0000000000000517

The new era of immunotherapy in cancer has led to a dramatical increase in patients survival but also to the emergence of a new type of immune-mediated toxicities mimicking known diseases but with special features. As the spectrum of checkpoint inhibitors is widening to many types of cancer expressing histological signs of immune blockade, new subtypes of immune-related adverse events are meant to be discovered and classified and among them new life-threatening situations that need to be quickly identified and require urgent treatment. We here report a case of refractory arterial hypotension with fever leading to diagnosis of combined immune-related adverse events associating hypophysitis, thyroiditis and colitis complicated by refractory arterial hypotension with fever.

aHopital Saint-Louis, Service de Dermatologie

bHopital Saint-Louis, Service de Réanimation

cHopital Lariboisère, Service d’Endocrinologie, Paris, France

Correspondence to Léo Plaçais, MD, Service de Dermatologie, Hôpital Saint Louis, 1 Avenue Claude Vellefaux, 75010 Paris, France Tel: +33 142 494 949; fax: +33 142 494 465; e-mail:

Received June 26, 2018

Accepted September 4, 2018

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.